ProQR Therapeutics N.V. (PRQR) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, losing 10.2% versus a loss of 33.5%. ProQR Therapeutics N.V. is the larger company by market cap ($225.1 million vs $222.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRQR | TRDA |
|---|---|---|
| Share price | $1.60 | $5.73 |
| Market cap | $225.08M | $222.91M |
| 1-day change | +1.59% | +3.53% |
| YTD return | -22.28% | -46.21% |
| 1-year return | -33.47% | -10.23% |
| 5-year return | -80.08% | — |
| EPS (TTM) | $-0.45 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.10 | $16.45 |
| 52-week low | $1.33 | $5.15 |
| Distance from 52-week high | -48.55% | -65.20% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +387.77% | +231.88% |
| Average volume | 796.41K | 355.24K |
| Shares outstanding | 141.12M | 38.94M |
| Employees | 186 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed PRQR by 23.2 percentage points over the past year.
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
PRQR vs TRDA FAQ
Which is bigger, ProQR Therapeutics N.V. or Entrada Therapeutics?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $225.08M compared with $222.91M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, PRQR or TRDA?
TRDA returned -10.23% over the past 12 months, compared with -33.47% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are ProQR Therapeutics N.V. and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.